Forte Biosciences (FBRX) Tops Q1 EPS by 16c

Forte Biosciences (NASDAQ: FBRX) reported Q1 EPS of ($0.36), $0.16 better than the analyst estimate of ($0.52).

“Forte has continued to make excellent progress in the fist quarter of 2021. As we have previously highlighted, our randomized clinical trial of FB-401 in atopic dermatitis patients 2 years of age and older, including adolescents and adults, completed enrollment. We expect to report the topline results from that trial in the third quarter of 2021. There is a significant unmet need for safe effective therapies, particularly for children suffering from atopic dermatitis and we are hopeful that FB-401 will address that need,” said Paul Wagner, Ph.D., CEO of Forte Biosciences. “In addition to the operational progress, two more patents have now issued, bringing the total number of patents covering FB-401 and our process to eleven as we continue to expand the intellectual property protection.”

For earnings history and earnings-related data on Forte Biosciences (FBRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ennis (EBF) Reports In-Line Q1 EPS
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook